Intellia Therapeutics Inc (NTLA) Stock Rating Upgraded by Zacks Investment Research

intellia-therapeutics-inc-ntla-stock-rating-upgraded-by-zacks-investment-research.jpg

Intellia Therapeutics Inc (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Several other equities analysts also recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Intellia Therapeutics in a report on Tuesday, August 23rd. Jefferies Group reissued a “buy” rating and set a $33.00 price target on shares of Intellia Therapeutics in a report on Wednesday, August 17th. Leerink Swann raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a report on Friday, August 5th. Finally, Credit Suisse Group AG assumed coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price objective for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Intellia Therapeutics presently has a consensus rating of “Buy” and an average price target of $35.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/intellia-therapeutics-inc-ntla-stock-rating-upgraded-by-zacks-investment-research-4.html

Shares of Intellia Therapeutics (NASDAQ:NTLA) opened at 19.72 on Wednesday. The firm’s market capitalization is $709.82 million. The firm’s 50 day moving average is $20.12 and its 200 day moving average is $22.57. Intellia Therapeutics has a 1-year low of $17.05 and a 1-year high of $30.40.
Large investors have recently bought and sold shares of the company. GLG Partners LP bought a new stake in Intellia Therapeutics during the second quarter valued at $100,000. Pacad Investment Ltd. acquired a new stake in shares of Intellia Therapeutics during the second quarter valued at approximately $117,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Intellia Therapeutics during the second quarter valued at approximately $190,000. Teachers Advisors Inc. acquired a new stake in shares of Intellia Therapeutics during the second quarter valued at approximately $235,000. Finally, Marshall Wace LLP acquired a new stake in shares of Intellia Therapeutics during the second quarter valued at approximately $244,000.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intellia Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Intellia Therapeutics Inc (NTLA) Stock Rating Upgraded by Zacks Investment Research"

Leave a comment

Your email address will not be published.


*